NovaBay Pharmaceuticals, Inc. (NBY) |
| 1.4699 -0.48 (-24.62%) 05-22 12:37 |
| Open: | 1.4699 |
| High: | 1.4699 |
| Low: | 1.4699 |
| Volume: | 86,826 |
| Market Cap: | 39(M) |
| PE Ratio: | -0.05 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 1.90 |
| Resistance 1: | 1.63 |
| Pivot price: | 1.53 |
| Support 1: | 1.20 |
| Support 2: | 1.00 |
| 52w High: | 99.75 |
| 52w Low: | 1.11 |
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Thu, 02 Apr 2026
NovaBay Pharma Rebrands as Stablecoin Development Corporation - The Globe and Mail
Mon, 30 Mar 2026
NovaBay Pharmaceuticals Announces Corporate Name Change to Stablecoin Development Corporation - VisionMonday.com
Mon, 23 Mar 2026
Stablecoin Development Corporation to Acquire 2.06 Billion SKY Tokens Following $134 Million Investment and Corporate Name Change from NovaBay Pharmaceuticals | NBY Stock News - Quiver Quantitative
Mon, 23 Mar 2026
NovaBay Pharmaceutical (NBY) pivoting to crypto - CoinDesk
Mon, 23 Mar 2026
Biotech stock NovaBay jumps 19% amid pivot, rebrand to Stablecoin Development Corporation - The Block
Thu, 12 Feb 2026
NovaBay Pharmaceuticals Announces 1-for-5 Reverse Stock Split - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |